Fig. 5From: A multi-center, single-arm, phase II study of anlotinib plus paclitaxel and cisplatin as the first-line therapy of recurrent/advanced esophageal squamous cell carcinomaProgression-free survival (PFS, c-Kit population). PFS was stratified by c-Kit levels (H-score ≤ 4 vs. H-score > 4). CI, confidence interval; HR, hazard ratioBack to article page